Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
64.71
+0.16 (0.25%)
Apr 29, 2025, 4:00 PM EDT - Market closed
Arcellx Revenue
In the year 2024, Arcellx had annual revenue of $107.94M, down -2.16%. Arcellx had revenue of $15.27M in the quarter ending December 31, 2024, a decrease of -75.83%.
Revenue (ttm)
$107.94M
Revenue Growth
-2.16%
P/S Ratio
32.11
Revenue / Employee
$662,184
Employees
163
Market Cap
3.56B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ACLX News
- 15 hours ago - Baron Health Care Fund Q1 2025 Top Net Purchases And Sales - Seeking Alpha
- 15 hours ago - Baron Health Care Fund Q1 2025 Top Contributors And Detractors - Seeking Alpha
- 5 weeks ago - Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors - Business Wire
- 6 weeks ago - Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month - GlobeNewsWire
- 6 weeks ago - Arcellx Impressive Safety Data Leaves Doubts - Seeking Alpha
- 2 months ago - Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights - Business Wire
- 2 months ago - Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference - Business Wire
- 5 months ago - Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients - Benzinga